• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)

    2/14/22 8:45:37 AM ET
    $OYST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OYST alert in real time by email
    SC 13G/A 1 p22-0375sc13ga.htm OYSTER POINT PHARMA, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  2)*
     

    Oyster Point Pharma, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    69242L106

    (CUSIP Number)
     

    December 31, 2021

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 69242L10613G/APage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    2,058,504 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    2,058,504 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,058,504 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.9%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. 69242L10613G/APage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    2,058,504 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    2,058,504 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,058,504 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.9%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. 69242L10613G/APage 4 of 7 Pages

     

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Oyster Point Pharma, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 202 Carnegie Center, Suite 109, Princeton, New Jersey 08540.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by:
       
      (i)

    RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the RTW Funds; and

     

      (ii) Mr. Roderick Wong ("Mr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:
       
      RTW Investments is a Delaware limited partnership.  Mr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the "Shares").

     

     

    CUSIP No. 69242L10613G/APage 5 of 7 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      69242L106

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: _____________________________

     

    Item 4. OWNERSHIP.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
       
      The percentages set forth herein are calculated based upon 26,163,861 Shares outstanding as of October 29, 2021 as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the Securities and Exchange Commission on November 4, 2021.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

     

    CUSIP No. 69242L10613G/APage 6 of 7 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.  The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.  RTW Master Fund Ltd., a RTW Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Shares.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 69242L10613G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    DATED: February 14, 2022
     
    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong  
    Name: Roderick Wong  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong  
    RODERICK WONG  

     

    Get the next $OYST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OYST

    DatePrice TargetRatingAnalyst
    8/11/2022$22.00Buy
    Chardan Capital Markets
    7/18/2022$20.00Buy
    H.C. Wainwright
    11/9/2021$30.00 → $23.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $OYST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Oyster Point Pharma with a new price target

      Chardan Capital Markets initiated coverage of Oyster Point Pharma with a rating of Buy and set a new price target of $22.00

      8/11/22 6:19:22 AM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Oyster Point Pharma with a new price target

      H.C. Wainwright initiated coverage of Oyster Point Pharma with a rating of Buy and set a new price target of $20.00

      7/18/22 7:31:49 AM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oyster Point Pharma downgraded by JP Morgan with a new price target

      JP Morgan downgraded Oyster Point Pharma from Overweight to Neutral and set a new price target of $23.00 from $30.00 previously

      11/9/21 4:30:34 AM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OYST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      PRINCETON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company's Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 11,300 shares of common stock to three new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan. Each stock option has an exercise price equal to $11.20 per share, Oyster Point Pharma's

      12/2/22 8:00:00 AM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of RBA, OYST, LFG, and IAA

      NEW YORK, NY / ACCESSWIRE / November 12, 2022 / Ritchie Bros. Auctioneers Incorporated (NYSE:RBA)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of IAA, Inc. to RBA for $10.00 per share in cash and 0.5804 shares of RBA common stock for each share of IAA common stock.If you are an RBA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected] Point Pharma, Inc. (NASDAQ:OYST)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connecti

      11/12/22 8:11:00 PM ET
      $IAA
      $LFG
      $OYST
      $RBA
      Other Specialty Stores
      Consumer Discretionary
      Power Generation
      Utilities
    • Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights

      TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3'22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care ProfessionalsNovember 1, 2022 Marked the First Anniversary of the Commercial Launch of TYRVAYA, with Over 97,000 Prescriptions Written as of October 21, 2022Expanded Patient Access and Commercial Coverage for TYRVAYA, with Up to Approximately 117 Million Lives Covered to DateOyster Point Pharma to be Acquired by Viatris, with the Transaction Expected to Close During Q1'23Enrollment Completed in the OLYMPIA Phase 2 Clinical Trial for Stage 1 Neurotrophic Keratopat

      11/10/22 4:05:00 PM ET
      $OYST
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OYST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TYRVAYA issued to OYSTER POINT PHARMA INC

      Submission status for OYSTER POINT PHARMA INC's drug TYRVAYA (ORIG-1) with active ingredient VARENICLINE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 213978, Application Classification: Type 3 - New Dosage Form

      10/19/21 7:27:01 PM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OYST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Invopps Gp Iv, L.L.C.

      4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)

      1/5/23 4:30:58 PM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Versant Venture Capital Vi, L.P.

      4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)

      1/4/23 6:11:53 PM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Behbahani Ali returned 13,639 shares to the company, closing all direct ownership in the company (for tax liability)

      4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)

      1/4/23 5:16:58 PM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OYST
    SEC Filings

    See more
    • SEC Form 15-12G filed by Oyster Point Pharma Inc.

      15-12G - Oyster Point Pharma, Inc. (0001720725) (Filer)

      1/13/23 5:10:52 PM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oyster Point Pharma Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits (Amendment)

      8-K/A - Oyster Point Pharma, Inc. (0001720725) (Filer)

      1/13/23 5:06:01 PM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Oyster Point Pharma Inc.

      EFFECT - Oyster Point Pharma, Inc. (0001720725) (Filer)

      1/6/23 12:15:13 AM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OYST
    Leadership Updates

    Live Leadership Updates

    See more
    • Oyster Point Pharma Announces Retirement of William J. Link From Board of Directors

      PRINCETON, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that William J. Link, Ph.D., is retiring from Oyster Point's Board of Directors, effective as of March 17, 2022. Dr. Link will continue to serve as a consultant to the company. "On behalf of the entire Oyster Point organization, we are eternally thankful to Dr. Link for his leadership and significant contributions over the years," said Jeffrey Nau, M.M.S, Ph.D., president and chief executive officer, Oy

      3/17/22 8:00:00 AM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oyster Point Pharma Announces New Chairperson Appointment to Board of Directors

      PRINCETON, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the appointment of a new Director and Chairperson to its Board of Directors. The Oyster Point Pharma Board of Directors is pleased to announce the appointment of Donald Santel as non-executive Chairperson and a Director of the Company and a member of the Compensation Committee. Don joined the Board on July 30, 2021, and will take over as Chairperson as Ali Behbahani, M.D. steps down as Chairperson, remaining a

      8/2/21 4:01:00 PM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers

      PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the appointment of Marian Macsai, M.D., as Chief Medical Officer, and Eric Carlson, Ph.D., as Chief Scientific Officer, both of whom will join the executive leadership team, effective December 7, 2020. “I’m thrilled to welcome Drs. Macsai and Carlson to the executive leadership team at Oyster Point, as both will help expand and strengthen our organization during this time of unprecedented growth,” said

      12/7/20 7:00:00 AM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OYST
    Financials

    Live finance-specific insights

    See more
    • Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights

      TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3'22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care ProfessionalsNovember 1, 2022 Marked the First Anniversary of the Commercial Launch of TYRVAYA, with Over 97,000 Prescriptions Written as of October 21, 2022Expanded Patient Access and Commercial Coverage for TYRVAYA, with Up to Approximately 117 Million Lives Covered to DateOyster Point Pharma to be Acquired by Viatris, with the Transaction Expected to Close During Q1'23Enrollment Completed in the OLYMPIA Phase 2 Clinical Trial for Stage 1 Neurotrophic Keratopat

      11/10/22 4:05:00 PM ET
      $OYST
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris

      Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), ("Oyster Point Pharma"), today announced that it has entered into a definitive agreement under which Viatris Inc. (NASDAQ:VTRS), a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmolo

      11/7/22 8:00:00 AM ET
      $OYST
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022

      PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. Eastern Time. Conference Call DetailsTo access the live call by phone, please register here to receive dial-in details or to select a call back. Webcast DetailsThe webcast will be made available on the compa

      11/2/22 4:02:00 PM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OYST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)

      SC 13G/A - Oyster Point Pharma, Inc. (0001720725) (Subject)

      2/14/23 4:59:07 PM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)

      SC 13G/A - Oyster Point Pharma, Inc. (0001720725) (Subject)

      2/14/23 10:05:19 AM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)

      SC 13D/A - Oyster Point Pharma, Inc. (0001720725) (Subject)

      1/13/23 4:09:33 PM ET
      $OYST
      Biotechnology: Pharmaceutical Preparations
      Health Care